LGALS3 and chronic kidney disease: Confirmation in larger, prospective, multicenter cohorts is needed to (i) validate reproducibility, (ii) establish actionable cut-offs, (iii) quantify incremental value over peptide-only and multi-marker baselines (e.g., ΔAUC, NRI, decision-curve analysis), (iv) compare head-to-head with sST2/galectin-3, and (v) test performance in obesity, CKD, and AF subgroups.